Autres langues Celldex Therapeutics, Inc.

Actions

CLDX

US15117B2025

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:13:45 29/09/2026			Varia. 5j.	Varia. 1 janv.
31,63 ^USD	+0,44%		-5,73%	+16,31%

22/09	Principales baisses à la mi-séance	MT
22/09	Transcript : Celldex Therapeutics, Inc. - Special Call

Autres langues

22/09	Top Midday Decliners
22/09	Celldex shares slip as safety concerns cloud skin drug trial win
22/09	Celldex Therapeutics, Inc. Reports Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab
22/09	Celldex's skin disease drug meets goals in two late-stage trials
22/09	Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
22/09	Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
08/09	Celldex to Present at Upcoming Investor Conference
06/08	Celldex: Q2 Earnings Snapshot
06/08	Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M
06/08	Celldex Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Celldex Reports Second Quarter Financial Results and Provides Corporate Update
22/07	Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says
21/07	Celldex Therapeutics Discontinues Phase 2 Study of Barzolvolimab in Prurigo Nodularis After Missing Primary Endpoint
21/07	Celldex to stop skin disease study after trial setback
21/07	Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
15/07	Celldex Therapeutics, Inc. Announces Retirement of Sam Martin from Senior Vice President, Effective on or About March 31, 2027
15/07	Celldex Therapeutics, Inc. Announces Retirement of Sam Martin as Chief Financial Officer, Effective on or About March 31, 2027
15/07	Celldex Therapeutics CFO Plans to Retire in 2027
15/07	Celldex Announces Planned Transition of Chief Financial Officer
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell Small Cap Comp Growth Benchmark
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 2500 Growth Benchmark
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 2000 Growth Benchmark
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 3000E Growth Benchmark
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 3000 Growth Benchmark
14/06	Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting